Gennaro Pagano, MD, MSc, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland, King’s College London, London, UK, emphasizes the importance of clarifying the relationship between neuronal damage and alpha-synuclein aggregation in Parkinson’s disease, as well as better understanding the pathways involved in synapse damage and dopaminergic neurodegeneration in this disease. Together with advances in technology, this knowledge will help identify novel therapeutic targets for Parkinson’s disease. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).

свернуть